These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 7893447)

  • 1. Autologous neutralizing antibodies and viral load in HIV-2-infected individuals.
    Tamalet C; Simon F; Dhiver C; Matheron S; de Micco P; Gastao JA; Brun-Vézinet F
    AIDS; 1995 Jan; 9(1):90-1. PubMed ID: 7893447
    [No Abstract]   [Full Text] [Related]  

  • 2. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection.
    Björling E; Scarlatti G; von Gegerfelt A; Albert J; Biberfeld G; Chiodi F; Norrby E; Fenyö EM
    Virology; 1993 Mar; 193(1):528-30. PubMed ID: 8438591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
    van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
    AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia.
    Günthard HF; Huber M; Kuster H; Shah C; Schüpbach J; Trkola A; Böni J
    Clin Infect Dis; 2009 Jun; 48(11):e117-20. PubMed ID: 19382874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity.
    Samuelsson A; Broström C; van Dijk N; Sönnerborg A; Chiodi F
    Virology; 1997 Nov; 238(2):180-8. PubMed ID: 9400591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
    Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.
    Bradney AP; Scheer S; Crawford JM; Buchbinder SP; Montefiori DC
    J Infect Dis; 1999 May; 179(5):1264-7. PubMed ID: 10191234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.
    Rodriguez SK; Sarr AD; Olorunnipa O; Popper SJ; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Infect Dis; 2006 Sep; 194(6):760-3. PubMed ID: 16941341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission.
    Lathey JL; Tsou J; Brinker K; Hsia K; Meyer WA; Spector SA
    J Infect Dis; 1999 Aug; 180(2):344-50. PubMed ID: 10395848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?
    Jülg B; Goebel FD
    Infection; 2005 Oct; 33(5-6):405-7. PubMed ID: 16258878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.
    Rodriguez SK; Sarr AD; MacNeil A; Thakore-Meloni S; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Virol; 2007 May; 81(10):5331-8. PubMed ID: 17301136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of neutralizing antibodies in HIV infection.
    Humbert M; Dietrich U
    AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 cross-neutralizing antibodies in German HIV-1-infected patients do not correlate with an antibody-binding pattern against different HIV-1 isolates.
    Jurkiewicz E; Petry H; Sutor GC; Lang S; Schedel I; Hunsmann G
    AIDS; 1995 Jan; 9(1):91-3. PubMed ID: 7893448
    [No Abstract]   [Full Text] [Related]  

  • 14. High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors.
    Wang Q; Shang H; Han X; Zhang Z; Jiang Y; Wang Y; Dai D; Diao Y
    Microbiol Immunol; 2008 Apr; 52(4):209-15. PubMed ID: 18426395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.
    Kelly HR; Urbanski M; Burda S; Zhong P; Konings F; Nanfack J; Tongo M; Kinge T; Achkar J; Nyambi P
    Hum Antibodies; 2005; 14(3-4):89-99. PubMed ID: 16720979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
    Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques.
    Zhang YJ; Putkonen P; Albert J; Ohman P; Biberfeld G; Fenyö EM
    Virology; 1994 May; 200(2):583-9. PubMed ID: 7909969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
    Donners H; Davis D; Willems B; van der Groen G
    J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.
    Beirnaert E; Nyambi P; Willems B; Heyndrickx L; Colebunders R; Janssens W; van der Groen G
    J Med Virol; 2000 Sep; 62(1):14-24. PubMed ID: 10935983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
    Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.